Lupin's US subsidiary, Lupin Pharmaceuticals, has received final approval for Suprax (Cefixime) chewable tablets, 100 mg, 150 mg and 200 mg from the US FDA.

Lupin filed 2 ANDAs bringing the cumulative filings as at the end of second quarter September 2010 reached to 132 ANDA filings, of which 45 have been approved by the US FDA.

Lupin Pharmaceuticals, Inc, headquartered in Baltimore, is dedicated to delivering high quality, affordable generic medicines and branded formulations. Lupin, India is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.